- Home
- IMNN vs GXAI Comparison
IMNN vs GXAI Comparison
Compare IMNN & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- GXAI
- Stock Information
- Founded
- IMNN 1982
- GXAI 2021
- Country
- IMNN United States
- GXAI United States
- Employees
- IMNN N/A
- GXAI N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- IMNN Health Care
- GXAI
- Exchange
- IMNN Nasdaq
- GXAI Nasdaq
- Market Cap
- IMNN 12.1M
- GXAI 10.1M
- IPO Year
- IMNN 1985
- GXAI 2023
- Fundamental
- Price
- IMNN $0.77
- GXAI $1.45
- Analyst Decision
- IMNN Buy
- GXAI
- Analyst Count
- IMNN 2
- GXAI 0
- Target Price
- IMNN $14.00
- GXAI N/A
- AVG Volume (30 Days)
- IMNN 5.4M
- GXAI 113.0K
- Earning Date
- IMNN 08-13-2025
- GXAI 08-12-2025
- Dividend Yield
- IMNN N/A
- GXAI N/A
- EPS Growth
- IMNN N/A
- GXAI N/A
- EPS
- IMNN N/A
- GXAI N/A
- Revenue
- IMNN N/A
- GXAI $27,740.00
- Revenue This Year
- IMNN N/A
- GXAI N/A
- Revenue Next Year
- IMNN N/A
- GXAI N/A
- P/E Ratio
- IMNN N/A
- GXAI N/A
- Revenue Growth
- IMNN N/A
- GXAI 9987.27
- 52 Week Low
- IMNN $0.37
- GXAI $1.00
- 52 Week High
- IMNN $3.65
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- GXAI 52.14
- Support Level
- IMNN $0.93
- GXAI $1.29
- Resistance Level
- IMNN $1.03
- GXAI $1.37
- Average True Range (ATR)
- IMNN 0.18
- GXAI 0.08
- MACD
- IMNN -0.10
- GXAI -0.01
- Stochastic Oscillator
- IMNN 1.39
- GXAI 46.15
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.